Shoulder Osteoarthritis
Conditions
Brief summary
Patients with shoulder osteoarthritis are suffering from pain and disabilities which lead to difficulties in life. The presence of platelet-rich plasma as regenerative therapy which helps in healing of damaged tissues like ligaments and joint might be of great benefit in managing such conditions.
Detailed description
Primary and secondary osteoarthritis of the shoulder occurs due to destruction of the articular surface of the humeral head and glenoid , Patient mainly presented with pain and decreases in the range of motion . Treatment of shoulder osteoarthritis is often controversial and is typically based on the patient's age, the severity of symptoms, and level of activity, radiographic findings, and medical comorbidities. The new era of management include regenerative therapy ,Platelet-rich plasma (PRP) is one of the regenerative therapy that prove its effect as injections of a concentration of a patient's own platelets to accelerate the healing of injured tendons, ligaments, muscles and joints.
Interventions
PROCEDUREInjection in the intraarticular space of glenohumeral joint
U/S guided injection of platelet rich plasma (PRP) or normal saline (NS)
Sponsors
Ain Shams University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Patient's age: From 21 years. * Acute symptoms on a background of at least a 3-month history of chronic pain or swelling of the shoulder joint with radiological confirmed (X-ray or MRI) * Mild or moderate osteoarthritis of the shoulder joint according to The Samilson-Prieto classification. * Numerical Rating Scale for pain scores greater than five on a 10 scale
Exclusion criteria
* Under 21 years of age * Severe osteoarthritis according to The Samilson-Prieto classification. (Figure 1) * Neuropsychiatric disorders. * Immunocompromised patients. * Active infection or malignancy at the joint. * Pregnancy and breastfeeding. * Patients may have thrombocytopenia, bleeding disorders, or on anticoagulant therapy. * Shoulder surgery within 3 months or inflammatory arthritis; previous infection of the shoulder joint.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in patient's pain score | 2 weeks after each injection | By using NUMERICAL PAIN SCALE patient will mention them pain score on scale from 1 to 10, where the pain score to be included in the study is 5 and more , we will measure pain score for each patient after 2 weeks from injection ,where decrease of the number from the initial recorded number before injection means improvement. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| change in the range of motion | 2 weeks after each injection | This out come will be evaluated by physiotherapist using a device called a goniometer. A goniometer is a metal or plastic handheld device with two arms. Numbers representing angular distance are on the device, The physiotherapist measures the initial angular distance before the injection, and after the injection by 2 weeks Normal range of active movement of the shoulder has been specified by the American Academy of Orthopedic Surgeons (AAOS) to be 180° for flexion and abduction and 90° for external rotation. |
Other
| Measure | Time frame | Description |
|---|---|---|
| change in the use of analgesic medication | 2 weeks after each injection | amount of analgesia that needed to inhibit pain, is the patient still in need to pain medication , or he cease it . |
Countries
Egypt
Outcome results
None listed